Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of efruxifermin in compensated cirrhosis due to NASH/MASH
2024-512895-36-00Phase 3Authorised
- Sponsor
- Akero Therapeutics
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Efruxifermin with Placebo (2 arms). Primary endpoints: Event-free survival and Fibrosis improvement without worsening of steatohepatitis at Week 96. Planned start Nov 2024; status: authorised.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2024-512895-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512895-36-00.